drugset
Drugs / CD19 CAR engineered autologous T-cells
last change Aug 2024 re-read 2 minutes ago

CD19 CAR engineered autologous T-cells

Cell therapy targets CD19

Developed for
B-cell acute lymphoblastic leukemia
Investigated by
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran · Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran · Sabz Biomedicals

Trials 1 · a red edge is where a trial was stopped

today NCT04653493 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04653493 Aug 2021 → Aug 2024 B-cell acute lymphoblastic leukemia Sabz Biomedicals Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CD19 CAR engineered autologous T-cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04653493 ↗
Modality Cell therapy “autologous Chimeric Antigen Receptor (CAR) T-cells” NCT04653493 ↗
Route Intravenous “Given IV” NCT04653493 ↗
Target CD19 “targeting CD19” NCT04653493 ↗